Advertisement
U.S. markets open in 2 hours 21 minutes
  • S&P Futures

    5,305.00
    -3.25 (-0.06%)
     
  • Dow Futures

    40,138.00
    -6.00 (-0.01%)
     
  • Nasdaq Futures

    18,488.00
    -15.75 (-0.09%)
     
  • Russell 2000 Futures

    2,136.00
    -2.40 (-0.11%)
     
  • Crude Oil

    82.23
    +0.88 (+1.08%)
     
  • Gold

    2,232.80
    +20.10 (+0.91%)
     
  • Silver

    24.80
    +0.05 (+0.19%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.99
    +0.21 (+1.64%)
     
  • GBP/USD

    1.2620
    -0.0018 (-0.14%)
     
  • USD/JPY

    151.3730
    +0.1270 (+0.08%)
     
  • Bitcoin USD

    70,762.45
    +698.01 (+1.00%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.29
    +22.31 (+0.28%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

CLASS ACTION DEADLINE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, OSTK, MTCH

BALA CYNWYD, PA / ACCESSWIRE / November 20, 2019 / Brodsky & Smith, LLC reminds investors of important approaching deadlines for lead plaintiff application regarding class action lawsuits against the following companies for violations of federal securities laws. If you purchased any of the below-listed stocks during the referenced time periods and want to discuss your legal rights, please contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at 877-534-2590. There is no cost or financial obligation to you.

MYRIAD GENETICS, INC. (MYGN)

Shares purchased between September 2, 2019 and August 13, 2019

Deadline: November 26, 2019

According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the FDA had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused Myriad to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on Myriad's revenue; and (v) as a result, Myriad's public statements were materially false and misleading at all relevant times.

Additional information can be found at http://www.brodskysmith.com/cases/myriad-genetics-inc-nasdaq-mygn/, or call: 877-534-2590. No cost or obligation.

OVERSTOCK.COM, INC. (OSTK)

Shares purchased between May 9, 2019, and September 23, 2019

Deadline: November 26, 2019

According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) it was not true that Overstock would be able to support the launch of its tZERO cryptocurrency with earnings or cash flow from its Retail operations; (ii) the foreseeable likelihood that Overstock's ability to accomplish its intended short squeeze would embolden the SEC or even market participants, such as major brokerage houses, to act to prevent this market manipulation; (iii) it was also not true that Overstock contained adequate systems of internal operational or financial controls; and (iv) the defendants lacked any reasonable basis to claim that Overstock was operating according to plan, or that Overstock could achieve guidance sponsored and/or endorsed by defendants.

Additional information can be found at http://www.brodskysmith.com/cases/overstock-com-inc-nasdaq-ostk/, or call: 877-534-2590. No cost or obligation.

MATCH GROUP, INC. (MTCH)

Shares purchased between August 6, 2019 and September 25, 2019

Deadline: December 2, 2019

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company used fake love interest ads to convince customers to buy and upgrade subscriptions; (2) that the Company made it difficult and confusing for consumers to cancel their subscriptions; (3) that, as a result, the Company was reasonably likely to be subject to regulatory scrutiny; (4) that the Company lacked adequate disclosure controls and procedures; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Additional information is available at http://www.brodskysmith.com/cases/match-group-inc-nasdaq-mtch/. No cost or obligation.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC



View source version on accesswire.com:
https://www.accesswire.com/567248/CLASS-ACTION-DEADLINE-Brodsky-Smith-LLC-Reminds-Investors-of-Looming-Deadlines-to-File-Lead-Plaintiff-Motions-Related-to-the-Following-Companies-MYGN-OSTK-MTCH

Advertisement